Latvian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Lappuse 1 no 29 rezultātiem
Kombic acid/sarganol bis-succinate and derivatives as potent apoptogens (antineoplastic agents) with high selectivity for cancer cells
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to Kombic Acid derivatives as anti-cancer agents. More particularly, the present invention relates to kombic acid bis-succinate (also known as sarganol bis-succinate) and the corresponding alkyl and aryl derivatives
Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE DISCLOSURE
This disclosure concerns agents that transiently decrease the partial pressure of oxygen in a tumor and methods of using them to increase the efficacy of hypoxia-sensitive agents to treat subjects with a tumor.
BACKGROUND
Hypoxia within regions of solid tumors is associated
Mitochondrially delivered anti-cancer compounds
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD
This invention relates, inter alia, to anti-cancer compounds and to methods for treating or preventing cancer. In particular, the invention concerns mitochondrially delivered pro-oxidant anti-cancer compounds that generate reactive oxygen species and induce apoptosis of cancerous
Method for the treatment of lung tumors
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
CROSS-REFERENCE TO RELATED APPLICATIONS
Not applicable.
BACKGROUND
Field of Invention
This invention relates to a process for treating primary or metastatic lung tumors by inhalation of the anticancer drug paclitaxel in an aerosol formulation comprising paclitaxel along with .alpha.-tocopheryl
Cabozantinib salts and their use as anti-cancer agents
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
This application is a Section 371 national phase entry of PCT application PCT/EP2016/056262, filed Mar. 22, 2016. This application also claims the benefit of the earlier filing date of European patent application 15160877.5, filed Mar. 25, 2015.
FIELD OF THE INVENTION
The present invention relates
Lyophilized preparation of cytotoxic dipeptides
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD
The present invention is directed to lyophilized pharmaceutical preparations comprising cytotoxic dipeptides or pharmaceutically acceptable salts thereof, methods for their preparation, compositions comprising the lyophilized pharmaceutical preparations and their use in the treatment
Lyophilized preparation of cytotoxic dipeptides
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD
The present invention is directed to lyophilized pharmaceutical preparations comprising cytotoxic dipeptides or pharmaceutically acceptable salts thereof, methods for their preparation, compositions comprising the lyophilized pharmaceutical preparations and their use in the treatment
Salt forms of E-2-methoxy-N-(3-{4-[3 methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-a cetamide and method of production
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
This invention relates to complexes of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-qu inazolin-6-yl}-allyl)-acetamide having the formula I: ##STR2##
Formula I in its free base form is described in co-pending U.S. Ser. No. 09/883,752, filed Jun.
Process for the preparation of macrocyclic metalloprotease inhibitors
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION
The present invention relates to processes for the preparation of macrocyclic molecules containing anti-succinate residues which inhibit metalloproteinases such as aggrecanase, and the production of tumor necrosis factor (TNF). The anti-succinates are formed by an Ireland
Process for the preparation of macrocyclic metalloprotease inhibitors
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION
The present invention relates to processes for the preparation of macrocyclic molecules containing anti-succinate residues which inhibit metalloproteinases such as aggrecanase, and the production of tumor necrosis factor (TNF). The anti-succinates are formed by an Ireland
Di-aspirin derivatives
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
RELATED APPLICATIONS
This application is a National Phase application of International Application No. PCT/GB2011/050284 filed Feb. 15, 2011, which claims priority to and the benefit of GB 1002530.2 filed Feb. 15, 2010, and the contents of both applications are incorporated by reference herein in
Formulations of indol-3-yl-2-oxoacetamide compounds
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
Cancer is a leading cause of death in developed countries. Despite continuing advances in diagnosis and treatment regimens, most existing treatment methods have undesirable side effects and limited efficacy. Treatment of cancer is complicated by the variety of mechanisms
Hydroxamic acid-based bifunctional chelating compounds
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the field of linkers attaching ion-chelating groups to biologic molecules such as proteins or nucleic acids as well as tissues such as blood cells. More particularly, the present invention relates to hydroxamic
Pharmaceutically acceptable salts of B-guanidinopropionic acid with improved properties and uses thereof
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND
.beta.-Guanidinopropionic acid (.beta.-GPA), also referred to as guanidinopropionic acid, beta-guanidinopropionic acid or, N-(aminoiminomethyl)-beta-alanine is a creatine analog. Studies on animals (rats, monkeys, hamsters) show that acidic guanidine derivatives such as .beta.-GPA can
Pharmaceutically acceptable salts of B-guanidinopropionic acid with improved properties and uses thereof
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND
.beta.-Guanidinopropionic acid (.beta.-GPA), also referred to as guanidinopropionic acid, beta-uanidinopropionic acid or, N-(aminoiminomethyl)-beta-alanine is a creatine analog. Studies on animals (rats, monkeys, hamsters) show that acidic guanidine derivatives such as .beta.-GPA can
Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne
- Darbojas 55 valodās
- Zāļu ārstniecības līdzekļi, kurus atbalsta zinātne
- Garšaugu atpazīšana pēc attēla
- Interaktīva GPS karte - atzīmējiet garšaugus atrašanās vietā (drīzumā)
- Lasiet zinātniskās publikācijas, kas saistītas ar jūsu meklēšanu
- Meklēt ārstniecības augus pēc to iedarbības
- Organizējiet savas intereses un sekojiet līdzi jaunumiem, klīniskajiem izmēģinājumiem un patentiem
Ierakstiet simptomu vai slimību un izlasiet par garšaugiem, kas varētu palīdzēt, ierakstiet zāli un redziet slimības un simptomus, pret kuriem tā tiek lietota.
* Visa informācija ir balstīta uz publicētiem zinātniskiem pētījumiem
